FMR LLC - 25 Jul 2023 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)

Role
Other*, 10%+ Owner
Signature
Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Issuer symbol
TSBX
Transactions as of
25 Jul 2023
Transactions value $
$0
Form type
4
Filing time
27 Jul 2023, 08:42:15 UTC
Previous filing
20 Jul 2023
Next filing
14 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSBX Common Stock Conversion of derivative security +91,663 91,663 25 Jul 2023 F-Prime Capital Partners Healthcare Fund V LP F1
transaction TSBX Common Stock Conversion of derivative security +106,496 +1.16% 198,159 25 Jul 2023 F-Prime Capital Partners Healthcare Fund V LP F1
transaction TSBX Common Stock Conversion of derivative security +150,809 +76.11% 348,968 25 Jul 2023 F-Prime Capital Partners Healthcare Fund V LP F1
transaction TSBX Common Stock Conversion of derivative security +483,684 +1.39% 832,652 25 Jul 2023 F-Prime Capital Partners Healthcare Fund V LP F1
transaction TSBX Common Stock Conversion of derivative security +296,396 296,396 25 Jul 2023 Impresa Fund III Limited Partnership F1
transaction TSBX Common Stock Conversion of derivative security +4,939 4,939 25 Jul 2023 F-Prime Capital Partners Healthcare Advisors Fund V LP F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSBX Series D Preferred Stock Conversion of derivative security -91,663 -100% 0 25 Jul 2023 Common Stock 91,663 F-Prime Capital Partners Healthcare Fund V LP F1
transaction TSBX Series C Preferred Stock Conversion of derivative security -106,496 -100% 0 25 Jul 2023 Common Stock 106,496 F-Prime Capital Partners Healthcare Fund V LP F1
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security -150,809 -100% 0 25 Jul 2023 Common Stock 150,809 F-Prime Capital Partners Healthcare Fund V LP F1
transaction TSBX Series B-1 Preferred Stock Conversion of derivative security -483,684 -100% 0 25 Jul 2023 Common Stock 483,684 F-Prime Capital Partners Healthcare Fund V LP F1
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security -296,396 -100% 0 25 Jul 2023 Common Stock 296,396 Impresa Fund III Limited Partnership F1
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security -4,939 -100% 0 25 Jul 2023 Common Stock 4,939 F-Prime Capital Partners Healthcare Advisors Fund V LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.